Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and 
remission of intestinal permeability in a rat non-alcoholic steatohepatitis model

Douhara,Akitoshi; Moriya,Kei; Yoshiji,Hitoshi; Noguchi,Ryuichi; Namisaki,Tadashi; Kitade,Mitsuteru; Kaji,Kosuke; Aihara,Yosuke; Nishimura,Norihisa; Takeda,Kosuke; Okura,Yasushi; Kawaratani,Hideto; Fukui,Hiroshi

doi:10.3892/mmr.2014.2995

Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model

Authors:
- Akitoshi Douhara
- Kei Moriya
- Hitoshi Yoshiji
- Ryuichi Noguchi
- Tadashi Namisaki
- Mitsuteru Kitade
- Kosuke Kaji
- Yosuke Aihara
- Norihisa Nishimura
- Kosuke Takeda
- Yasushi Okura
- Hideto Kawaratani
- Hiroshi Fukui
View Affiliations

Affiliations: Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634‑8521, Japan
Published online on: November 24, 2014 https://doi.org/10.3892/mmr.2014.2995
Pages: 1693-1700
Copyright: © Douhara et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous clinical studies have demonstrated that endotoxin/toll‑like receptor 4 (TLR4) signaling is critical in the inflammatory pathways associated with non‑alcoholic steatohepatitis (NASH). In human and animal studies, NASH was associated with portal lipopolysaccharide (LPS) and the plasma LPS level was hypothesized to be associated with small intestinal bacterial overgrowth, change in composition of the microbiota and increased intestinal permeability. The aim of the present study was to investigate the roles of endogenous endotoxin and TLR4 in the pathogenesis of NASH. The effects of antibiotics were assessed in vivo using a choline deficiency amino acid (CDAA)‑induced experimental liver fibrosis model. Antibiotics, including polymyxins and neomycins, were orally administered in drinking water. Antibiotics attenuated hepatic stellate cell (HSC) activation and liver fibrosis via TGF‑β and collagen in an experimental hepatic fibrosis model. The mechanism by which antibiotics attenuated LPS‑TLR4 signaling and liver fibrosis was assessed. Notably, TLR4 mRNA level in the liver was elevated in the CDAA group and the CDAA‑induced increase was significantly reduced by antibiotics. However, no significant differences were observed in the intestine among all groups. Elevated mRNA levels of LPS binding protein, which was correlated with serum endotoxin levels, were recognized in the CDAA group and the CDAA‑induced increase was significantly reduced by antibiotics. The intestinal permeability of the CDAA group was increased compared with the choline‑supplemented amino acid group. The tight junction protein (TJP) in the intestine, determined by immunohistochemical analysis was inversely associated with intestinal permeability. Antibiotics improved the intestinal permeability and enhanced TJP expression. Inhibition of LPS‑TLR4 signaling with antibiotics attenuated liver fibrosis development associated with NASH via the inhibition of HSC activation. These results indicated that reduction of LPS and restoration of intestinal TJP may be a novel therapeutic strategy for treatment of liver fibrosis development in NASH.

View Figures

View References

1	Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
2	Henao-Mejia J, Elinav E, Jin C, et al: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 482:179–185. 2012.PubMed/NCBI
3	Ekstedt M, Franzen LE, Mathiesen UL, et al: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 44:865–873. 2006. View Article : Google Scholar : PubMed/NCBI
4	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
5	Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M and Wallace M: Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 47:571–579. 2007. View Article : Google Scholar : PubMed/NCBI
6	Akira S and Takeda K: Toll-like receptor signaling. Nat Rev Immunol. 4:499–511. 2004. View Article : Google Scholar : PubMed/NCBI
7	Jagavelu K, Routray C, Shergill U, O’Hara SP, Faubion W and Shah VH: Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver. Hepatology. 52:590–601. 2010. View Article : Google Scholar : PubMed/NCBI
8	Seki E, de Minicis S, Osterreicher CH, et al: TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 13:1324–1332. 2007. View Article : Google Scholar : PubMed/NCBI
9	Endo H, Niioka M, Kobayashi N, Tanaka M and Watanabe T: Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: New insight into the probiotics for the gut-liver axis. PLoS One. 8:e633882013. View Article : Google Scholar : PubMed/NCBI
10	Ruiz AG, Casafont F, Crespo J, et al: Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 17:1374–1380. 2007. View Article : Google Scholar : PubMed/NCBI
11	Musso G, Gambino R and Cassader M: Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol. 21:76–83. 2010. View Article : Google Scholar
12	Szabo G, Bala S, Petrasek J and Gattu A: Gut-liver axis and sensing microbes. Dig Dis. 28:737–744. 2010. View Article : Google Scholar : PubMed/NCBI
13	Nguyen AT, Mandard S, Dray C, et al: Lipopolysacch arides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes. 63:471–482. 2014. View Article : Google Scholar
14	Miele L, Valenza V, La Torre G, et al: Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 49:1877–1887. 2009. View Article : Google Scholar : PubMed/NCBI
15	Ruberto F, Ianni S, Babetto C, et al: Polymyxin-B endotoxin removal device: making the point on mechanisms of action, clinical effectiveness and possible future applications: review. Infect Disord Drug Targets. 13:128–32. 2013. View Article : Google Scholar : PubMed/NCBI
16	Yoshiji H, Kuriyama S, Yoshii J, et al: Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 34:745–750. 2001. View Article : Google Scholar : PubMed/NCBI
17	Kaji K, Yoshiji H, Ikenaka Y, et al: Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol. 49:481–491. 2014. View Article : Google Scholar
18	Roh YS and Seki E: Toll-like receptors in alcoholic liver disease, non-alcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol. 28:38–42. 2013. View Article : Google Scholar : PubMed/NCBI
19	Schumann RR: Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. Biochem Soc Trans. 39:989–993. 2011. View Article : Google Scholar : PubMed/NCBI
20	Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM and Roy NC: Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 141:769–776. 2011. View Article : Google Scholar : PubMed/NCBI
21	Seki E and Schnabl B: Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 590:447–458. 2012. View Article : Google Scholar :
22	Guo S, Al-Sadi R, Said HM and Ma TY: Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol. 182:375–387. 2013. View Article : Google Scholar :
23	Brun P, Castagliuolo I, Di Leo V, et al: Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 292:G518–G525. 2007. View Article : Google Scholar
24	Du Plessis J, Vanheel H, Janssen CE, et al: Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol. 58:1125–1132. 2013. View Article : Google Scholar : PubMed/NCBI
25	Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, et al: Intestinal mucosal proliferation, apoptosis and oxidative stress in patients with liver cirrhosis. Ann Hepatol. 12:301–307. 2013.PubMed/NCBI
26	Assimakopoulos SF, Tsamandas AC, Louvros E, et al: Intestinal epithelial cell proliferation, apoptosis and expression of tight junction proteins in patients with obstructive jaundice. Eur J Clin Invest. 41:117–125. 2011. View Article : Google Scholar
27	Finamore A, Massimi M, Conti Devirgiliis L and Mengheri E: Zinc deficiency induces membrane barrier damage and increases neutrophil transmigration in Caco-2 cells. J Nutr. 138:1664–1670. 2008.PubMed/NCBI
28	Chiba M, Katayama K, Takeda R, et al: Diuretics aggravate zinc deficiency in patients with liver cirrhosis by increasing zinc excretion in urine. Hepatology Research. 43:365–373. 2013. View Article : Google Scholar
29	Mohammad MK, Zhou Z, Cave M, Barve A and McClain CJ: Zinc and liver disease. Nutr Clin Pract. 27:8–20. 2012. View Article : Google Scholar : PubMed/NCBI
30	De Minicis S, Rychlicki C, Agostinelli L, et al: Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 59:1738–1749. 2014. View Article : Google Scholar